scholarly journals Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030

2018 ◽  
Vol 34 (1) ◽  
pp. 40-48 ◽  
Author(s):  
Jess Howell ◽  
Alisa Pedrana ◽  
Benjamin C Cowie ◽  
Joseph Doyle ◽  
Aneley Getahun ◽  
...  
Keyword(s):  
New Zealand ◽  
Viral Hepatitis ◽  
World Health Organization ◽  
Pacific Islands ◽  
World Health ◽  
The Pacific ◽  
Health Organization

scholarly journals Risk posed by the Ebola epidemic to the Pacific islands: findings of a recent World Health Organization assessment

2015 ◽  
Vol 6 (2) ◽  
pp. 45-50 ◽  
Author(s):  
Adam T Craig ◽  
Axelle Ronsse ◽  
Kate Hardie ◽  
Boris I Pavlin ◽  
Viema Biaukula ◽  
...  
Keyword(s):  
World Health Organization ◽  
Pacific Islands ◽  
World Health ◽  
The Pacific ◽  
Health Organization

scholarly journals Pharmacotherapeutic management of chronic viral hepatitis

2021 ◽  
Vol 2 (4) ◽  
pp. 1-8
Author(s):  
Gabriela Mitea ◽  
Marius Daniel Radu ◽  
Ana Maria Ionescu ◽  
Nicoleta Blebea
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
World Health Organization ◽  
Geographical Area ◽  
Chronic Viral Hepatitis ◽  
World Health ◽  
Effective Vaccine ◽  
Special Importance ◽  
The World ◽  
Health Organization

In infectious diseases, viral hepatitis has an increased incidence, being an important cause of morbidity and mortality, being a "sentinel" indicator of the socio-economic and hygienic-cultural standard of a geographical area. The World Health Organization (WHO) admits the following types of hepatitis viruses: A, B, B + D, C, E, F and G. Among the viral entities recognized by the WHO, a special importance in terms of incidence, evolution over time with the risk of chronicity and the therapeutic options are presented by hepatitis B and C. There is currently an effective vaccine as well as treatment for hepatitis B. There is no vaccine for hepatitis C, but in recent years considerable progress has been made in treating this disease. Also, the introduction of drugs known as direct-acting antivirals makes it possible to cure over 90% of patients within 2-3 months. But in many countries, current drug policies, regulations and prices keep treatment out of the reach of most people with hepatitis. Eradication of viral hepatitis is possible if greater emphasis is placed on prevention, diagnosis and treatment. Vaccination is very important, as it is possible for types A and B of hepatitis. Early diagnosis is also extremely important, given that there are currently very effective drugs that can prevent the development of liver cancer. The WHO also noted that about two million people worldwide become ill each year due to the reuse of syringes and stressed the importance of checking blood donors to see if they are not carriers of hepatitis B or C viruses. Therefore, the purpose of this article is to highlight the pharmacological treatment and the main therapeutic and prevention schemes currently used for patients with these liver diseases. The paper was based on the most popular methods of identification of the latest international information about the treatment of hepatitis (by electronic search using Pubmed, SciFinder, Scirus, GoogleScholar and Web of Science). We also consulted the global literature cited in the hepatitis database of the World Health Organization (WHO) updated frequent from the current literature on this topic.

scholarly journals Manual para la elaboración y la evaluación de los planes nacionales contra las hepatitis virales

2017 ◽  
Keyword(s):  
Viral Hepatitis ◽  
World Health Organization ◽  
World Health ◽  
Creative Commons ◽  
Health Organization

[Resumen]: Este manual es el producto de un trabajo que comenzó en enero del 2012 con una misión de la Organización Mundial de la Salud (OMS) en Egipto. Tan pronto como se creó el Programa Mundial contra la Hepatitis en diciembre del 2011, el personal de la OMS se desplazó a El Cairo con el propósito de respaldar la respuesta nacional a las hepatitis. Esta circunstancia brindó una buena oportunidad de ensayar sobre el terreno una “lista de verificación”, con el fin de investigar la situación de la hepatitis en el país y la respuesta nacional a la enfermedad. Esta lista de verificación se elaboró específicamente para la misión y se ha revisado en muchas ocasiones después de este ensayo inicial, a partir de la retroinformación de numerosas personas. La lista se presenta ahora en el anexo 4 del manual como una guía temática para la evaluación de un programa nacional contra las hepatitis. La versión preliminar del manual se utilizó en el Pakistán, Arabia Saudita, Omán, Indonesia, Kuwait, Mongolia y Georgia durante las evaluaciones del país y como guía de la planificación del 2013 al 2015. A medida que se ampliaba el trabajo de la OMS en el campo de las hepatitis, los países empezaron a solicitar orientación para su elaboración de los planes nacionales contra las hepatitis. Dado que una respuesta integral a las hepatitis virales abarca muchas esferas de trabajo, fue importante reunir toda la orientación pertinente de la OMS a fin de facilitar la consulta. Por esta razón, la sección del manual sobre la planificación “general” es breve a propósito y contiene referencias a los documentos actuales de la OMS sobre esta disciplina de trabajo; se ha dedicado más espacio a la información y las orientaciones vigentes que son específicas de la respuesta a las hepatitis. El presente manual contiene referencias extensas a los documentos y enlaces sobre temas específicos como la seguridad de la sangre, la seguridad de las inyecciones, la vacunación y la reducción de daños, entre otros... Versión oficial en español de la obra original en ingles. Manual for the development and assessment of national viral hepatitis plan: a provisional document. © World Health Organization 2015. ISBN 978-92-4-150935-0. Algunos derechos reservados. Esta obra está disponible en virtud de la licencia 3.0 OIG Reconocimiento-NoComercial-CompartirIgual de Creative Commons (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

The socioeconomic context of migrants and minorities

1983 ◽  
Vol 15 (S8) ◽  
pp. 111-127 ◽  
Author(s):  
David C. Pitt
Keyword(s):  
New Zealand ◽  
World Health Organization ◽  
World Health ◽  
Socioeconomic Context ◽  
Anthropological Study ◽  
Health Organization

This paper is based on the author's experiences during first, participation in an anthropological study of migrants, particularly Samoan migrants, in New Zealand over a period of 10 years in the late 1960s–mid- 1970s (Pitt & MacPherson, 1975) and secondly, participation over the last 3 years in a World Health Organization programme concerned with promoting the health and welfare of children, many of whom were migrants living in poverty.

scholarly journals Iodine status of New Zealand residents as assessed by urinary iodide excretion and thyroid hormones

1997 ◽  
Vol 78 (6) ◽  
pp. 901-912 ◽  
Author(s):  
Christine D. Thomson ◽  
Andrew J. Colls ◽  
John V. Conaglen ◽  
Matthew Macormack ◽  
Martin Stiles ◽  
...  
Keyword(s):  
New Zealand ◽  
Thyroid Hormone ◽  
Blood Transfusion ◽  
World Health Organization ◽  
International Committee ◽  
World Health ◽  
Urine Specimen ◽  
Normal Ranges ◽  
Positive Correlations ◽  
Health Organization

The aims of this study were (1) to compare various measures of I status, and (2) to assess urinary I and thyroid hormone status of residents of two areas of New Zealand where, before the iodization of salt, goitre was endemic due to low soil I. A total of 189 subjects (102 males, eighty-seven females) were recruited from the Dunedin Blood Transfusion Centre, and 144 (sixty-seven males, seventyseven females) from the Waikato Blood Transfusion Centre between November 1993 and June 1994. Blood was taken for thyroid hormone assays, and subjects collected a fasting overnight urine specimen, a double-voided fasting urine sample, and a complete 24 h specimen for iodide and creatinine analyses. Positive correlations (P < 0.0001) between daily iodide excretion and iodide concentrations in fasting and double-voided fasting urines, identical median values for iodide concentrations in the three samples, and similar numbers of subjects classified as at risk from I deficiency disorders according to the International Committee for the Control of Iodine Deficiency Disorders/World Health Organization categories (World Health Organization, 1994) confirmed indications from earlier studies that fasting urine samples were suitable for population studies. However 24 h urinary iodide excretion remains the recommended measure for individual I status. Waikato residents excreted more iodide in urine and all measures were significantly greater than for Otago residents. However median urinary iodide excretions for both areas (60 and 76 μg/d for Otago and Waikato respectively) were considerably lower than those reported previously for New Zealand. Thyroid hormone concentrations were within normal ranges. Our findings suggest that I status of New Zealanders may no longer be considered adequate and may once again be approaching levels of intake associated with clinical I deficiency.

Sign in / Sign up

Export Citation Format

Share Document